Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

July 31, 2014

Conditions
Gastric CancerPancreatic CancerHepatocellular CancerColon Cancer
Interventions
DRUG

Tranexamic acid

"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"

OTHER

Standard of care

Includes routine surgical care involved in preventing blood loss during and after surgery.

Trial Locations (1)

0977

Tribhuvan University Teaching Hospital, Kathmandu

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Tribhuvan University Teaching Hospital, Institute Of Medicine.

OTHER